Dr. Bauml Discusses the FLAURA Study in NSCLC
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non—small cell lung cancer (NSCLC).
FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).
Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.
Related Videos
Related Content
